Filing Details
- Accession Number:
- 0000950170-24-003087
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-08 18:14:29
- Reporting Period:
- 2024-01-05
- Accepted Time:
- 2024-01-08 18:14:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1937653 | Zymeworks Inc. | ZYME | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1915257 | Christopher Astle | C/O Zymeworks Inc. 108 Patriot Drive, Suite A Middletown DE 19709 | Svp & Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-05 | 10,500 | $0.00 | 12,497 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-05 | 4,563 | $10.65 | 7,934 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-01-08 | 1,431 | $11.22 | 6,503 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Disposition | 2024-01-05 | 10,500 | $0.00 | 10,500 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-01-05 | 50,000 | $0.00 | 50,000 | $10.56 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2024-01-05 | 30,000 | $0.00 | 30,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 21,000 | No | 4 | M | Direct | ||
| 50,000 | 2034-01-04 | No | 4 | A | Direct | |
| 30,000 | No | 4 | A | Direct |
Footnotes
- Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023.
- Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
- The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024.
- Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
- The RSUs vest in three equal annual installments beginning on January 5, 2025.
Billionaire Hedge Funds
